The idea was both simple and powerful.

Parkinson's disease has long been associated with Lewy bodies and Lewy neurites—abnormal pathological structures found in affected regions of the nervous system.

For decades, researchers could see these structures under the microscope. They knew they were closely linked to Parkinson's disease. What they did not fully understand was what they were made of.

That changed in the late 1990s.

Researchers identified alpha-synuclein as a major constituent of Lewy bodies and Lewy neurites. Suddenly, a protein that had attracted relatively little attention appeared to be sitting inside one of the defining pathological hallmarks of Parkinson's disease.

The implications were difficult to ignore.

If alpha-synuclein was consistently present within the characteristic pathology of the disease, perhaps it was not merely accompanying Parkinson's disease.

Perhaps it was participating in the disease process itself.

The hypothesis that emerged was straightforward.

Alpha-synuclein can adopt abnormal conformations.

Misfolded alpha-synuclein can aggregate.

Aggregated alpha-synuclein is strongly implicated in Lewy body disease.

But the exact relationship between aggregation, neuronal dysfunction, toxicity, and cell death remains unresolved.

That distinction matters.

The presence of alpha-synuclein within Lewy pathology does not prove that alpha-synuclein alone causes Parkinson's disease.

Lewy bodies may represent toxic structures, failed clearance products, markers of cellular stress, or, in some contexts, even attempts by the cell to sequester harmful protein species.

The biology remains unsettled.

Still, the therapeutic idea was compelling.

If pathological alpha-synuclein contributes meaningfully to disease progression, then preventing aggregation—or interrupting the processes that allow pathological alpha-synuclein to accumulate and spread—might slow disease progression itself.

Not improve symptoms.

Not replace dopamine.

Potentially alter the course of Parkinson's disease.

For a field that had spent decades treating symptoms rather than progression, that possibility was enormously attractive.

Scientific ideas rarely become influential because of a single experiment.

They become influential when independent lines of evidence begin pointing toward the same biological explanation.

For alpha-synuclein, that is exactly what seemed to happen.

The first clue came from pathology.

Alpha-synuclein was identified as a major component of Lewy bodies and Lewy neurites—the pathological hallmarks of Parkinson's disease and other Lewy body disorders.

That finding linked the protein directly to the disease process.

But pathology alone cannot establish causation.

Proteins found within diseased tissue may be drivers, bystanders, compensatory responses, or consequences of another upstream process.

Researchers needed additional evidence.

The next major clue came from genetics.

Rare families with inherited Parkinson's disease were found to carry mutations in the SNCA gene, which encodes alpha-synuclein.

Suddenly, the same protein appeared in two very different places:

Within the defining pathology of the disease.

And within the genetic cause of certain familial forms of Parkinson's disease.

Researchers were no longer looking at two isolated observations. The same protein was now emerging from pathology and human genetics. That kind of convergence is difficult for a scientific field to ignore.

The story became even more compelling when researchers discovered that some individuals developed Parkinson's disease because they carried additional copies of the SNCA gene.

In these families, the gene itself was not necessarily altered by a point mutation.

Instead, affected individuals carried additional copies of the gene, resulting in increased alpha-synuclein expression.

SNCA duplications and triplications supported the idea that alpha-synuclein dosage could matter.

Higher alpha-synuclein expression was associated with disease, and in some families, greater gene dosage appeared to correlate with earlier onset or more severe disease.

This did not prove that the same mechanism explains all sporadic Parkinson's disease.

But it strongly suggested that alpha-synuclein biology could be sufficient to produce a Parkinsonian neurodegenerative syndrome in at least some humans.

Evidence also emerged from experimental biology.

In laboratory systems, misfolded alpha-synuclein can act as a template that promotes further alpha-synuclein misfolding.

In cellular and animal models, pathological alpha-synuclein can induce aggregation in previously unaffected cells.

These findings led to the proposal that alpha-synuclein might propagate through the nervous system in a prion-like manner.

That term requires care.

"Prion-like" does not mean that Parkinson's disease is infectious in the classical prion disease sense.

It means that, in experimental systems, abnormal protein conformations can seed further misfolding and spread pathology-like changes from one cell to another.

Additional support came from observations in transplanted fetal dopaminergic neurons.

Years after transplantation into patients with Parkinson's disease, some grafted neurons were found to contain Lewy body-like pathology.

These findings were striking because the grafted neurons had originally come from healthy fetal tissue.

Many researchers viewed this as consistent with the possibility that pathological alpha-synuclein could spread from affected host tissue into previously healthy neurons.

But the interpretation remains debated.

The number of reported cases was small.

The graft environment was biologically unusual.

And Lewy body-like pathology in grafted neurons does not, by itself, establish a single mechanism of human disease progression.

Still, these observations emerged during a period when protein aggregation was becoming a dominant theme in neurodegenerative disease research.

Alzheimer's disease research was increasingly focused on amyloid-beta and tau.

Prion diseases had demonstrated that proteins could adopt self-propagating pathological conformations.

Tau pathology was also being investigated as a spreading proteinopathy.

Alpha-synuclein appeared to fit naturally within this broader biological framework.

By the early 2000s, many researchers viewed alpha-synuclein as one of the most coherent biological frameworks yet proposed for Parkinson's disease.

Pathology pointed toward alpha-synuclein.

Genetics pointed toward alpha-synuclein.

Experimental biology pointed toward alpha-synuclein.

Individually, none of these observations proved the hypothesis.

Together, they made it extraordinarily compelling.

Looking back, it is difficult to see how the field could have avoided becoming fascinated by it.

Once alpha-synuclein emerged as one of the leading biological hypotheses in Parkinson's disease, the next question became unavoidable.

Could targeting it actually change the course of the disease?

Early experimental studies gave researchers reason for optimism.

In cellular and animal models, reducing pathological alpha-synuclein often appeared beneficial.

Monoclonal antibodies could bind extracellular alpha-synuclein, and several experimental studies suggested that lowering extracellular alpha-synuclein might interfere with the proposed propagation of pathological protein aggregates.

But these findings came with important limitations.

Many experimental models relied on alpha-synuclein overexpression, toxin-induced injury, or artificially seeded pathology. None fully reproduced the biology, timescale, heterogeneity, or clinical complexity of human Parkinson's disease.

Still, the preclinical evidence was sufficiently encouraging to launch one of the most ambitious therapeutic programs in Parkinson's disease research.

Multiple alpha-synuclein-targeted therapies entered clinical development.

Among the most prominent were the monoclonal antibodies cinpanemab and prasinezumab.

The therapeutic logic appeared straightforward.

If pathological alpha-synuclein contributes meaningfully to disease progression, then neutralizing the relevant extracellular alpha-synuclein species might slow progression itself.

But that remained a therapeutic hypothesis.

It was not yet an established clinical fact.

Clinical trials are where biologically plausible ideas are tested against the complexity of human disease.

And that is where the story became more complicated.

Cinpanemab was evaluated in the Phase II SPARK trial.

The study did not demonstrate a meaningful clinical benefit, and available biomarker analyses did not provide convincing evidence of target-related disease modification.

Development of cinpanemab was subsequently discontinued.

Prasinezumab has followed a more nuanced path.

In PASADENA, the trial did not meet its primary endpoint.

However, several secondary, exploratory, and longer-term analyses suggested possible signals affecting motor outcomes. These findings were hypothesis-generating rather than definitive.

PADOVA likewise failed to meet its primary endpoint.

Nevertheless, numerical trends and subgroup analyses were considered sufficiently encouraging for Roche and Genentech to continue development and advance prasinezumab into Phase III evaluation.

That distinction is important.

Prasinezumab has not demonstrated that alpha-synuclein immunotherapy is disease-modifying.

Equally, it has not been abandoned in the way cinpanemab was.

The broader conclusion is therefore necessarily cautious.

Targeting alpha-synuclein remains biologically plausible.

But clinical trials have not yet established that therapies directed against extracellular alpha-synuclein reliably slow Parkinson's disease progression.

Perhaps the most important lesson is not that the hypothesis failed.

It is that a biologically compelling hypothesis does not automatically translate into a clinically effective therapy.

The dramatic breakthrough many researchers hoped for has not yet arrived.

The hypothesis survived.

The certainty did not.

For nearly three decades, alpha-synuclein has been one of the most intensively studied targets in Parkinson's disease research. Yet one of the most important questions has shifted from "Can we target it?" to "Are we targeting the right biology, at the right time, in the right patients?"

One possible interpretation is that the alpha-synuclein hypothesis is wrong.

But science is rarely that simple.

A more useful question is why such a biologically compelling idea has not yet translated into equally compelling clinical results.

Several explanations remain plausible.

Researchers may be targeting the right biological process, but intervening too late in the disease course.

Alpha-synuclein may contribute meaningfully to disease progression without being its only driver.

The most pathogenic alpha-synuclein species may not be the ones current therapies neutralize most effectively.

Extracellular antibody therapies may have limited impact on intracellular pathology.

Clinical trials may be enrolling patients after the critical biological window for intervention has already begun to close.

Or Parkinson's disease may represent multiple overlapping disease processes—mitochondrial dysfunction, lysosomal impairment, neuroinflammation, genetic susceptibility, environmental exposures, and disrupted proteostasis—such that no single therapeutic target is sufficient to meaningfully alter progression.

At present, none of these explanations has been definitively established.

What has changed is not the existence of evidence supporting alpha-synuclein.

It is our interpretation of that evidence.

Alpha-synuclein has shifted from a seemingly unifying explanation to a more qualified—and more complex—biological framework.

Not because the evidence disappeared.

But because the evidence became more complicated.

And perhaps that is the real lesson.

Scientists did not become fascinated with alpha-synuclein because of a single fashionable idea.

They became fascinated with it because pathology, genetics, experimental biology, transplantation studies, and clinical reasoning all appeared to converge on the same biological hypothesis.

For a time, it seemed possible that the field had identified a central thread running through Lewy body Parkinson's disease.

Whether that thread explains enough of the disease to produce meaningful disease modification remains unknown.

For now, alpha-synuclein remains one of the most important biological suspects in Parkinson's disease.

But after more than twenty-five years of investigation, the case is still open.

—

Think Beyond the Headline.

Alpha-synuclein was never the only attempt to slow Parkinson's disease.

For decades, researchers have pursued therapies designed to alter the course of the disease itself—not just its symptoms. Many were built on sound biological reasoning. Some reached large clinical trials. Yet, one after another, they failed to deliver the breakthrough the field had hoped for.

In the next issue of The Clinical Logic, we'll investigate why.